{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-007836","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.335318+00:00","generated_at":"2026-05-23T01:54:03.989124+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite launches generic Percocet (oxycodone/acetaminophen) tablets in 3 strengths","bullets":["Launched generic oxycodone HCl/acetaminophen tablets in 5/325, 7.5/325, and 10/325 mg strengths.","Product is indicated for moderate to moderately severe pain, marketed under Elite Laboratories label.","IQVIA reported 2024 brand sales of ~$317 million for the reference product."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-007836","json":"https://secwatch.observer/filing/0001641172-25-007836.json","markdown":"https://secwatch.observer/filing/0001641172-25-007836.md","text":"https://secwatch.observer/filing/0001641172-25-007836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225007836/0001641172-25-007836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225007836/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:54:03.989124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}